Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A method of removing amyloid deposits from a subject comprising administering to the subject amyloid fibrils comprising immunoglobulin light chain polypeptide or whole immunoglobulin light chain polypeptide, heterologous to the amyloid fibrils in the subject, in an effective amount to generate an immune response, wherein the immune response promotes the removal of amyloid deposits from the subject, ~~and wherein the amyloid fibrils do not comprise amyloid β protein~~.

Claims 2-31 (canceled)

Claim 32 (currently amended): A method of claim 1 ~~or 2~~, wherein the amyloid fibrils are synthetic amyloid fibrils.

Claim 33 (currently amended): A method of claim 1 ~~or 2~~, wherein the amyloid fibrils are recombinant amyloid fibrils.

Claim 34 (currently amended): A method of claim 1 ~~or 2~~, wherein the amyloid fibrils are naturally occurring amyloid fibrils.

Claims 35-38 (canceled)

Claim 39 (currently amended): A method of claim 1 ~~or 2~~, wherein the subject is a mammal.

Claim 40 (previously presented): A method of claim 39, wherein the mammal is a human.

Claim 41 (previously presented): A method of claim 1, wherein about 10% or more of the amyloid deposits are removed as compared to the subject without treatment of amyloid fibrils.

Claim 42 (previously presented): A method of claim 41, wherein about 20% or more of the amyloid deposits are removed as compared to the subject without treatment of amyloid fibrils.

Claim 43 (previously presented): A method of claim 42, wherein about 30% or more of the amyloid deposits are removed as compared to the subject without treatment of amyloid fibrils.

Claim 44 (previously presented): A method of claim 43, wherein about 40% or more of the amyloid deposits are removed as compared to the subject without treatment of amyloid fibrils.

Claim 45 (previously presented): A method of claim 44, wherein about 50% or more of the amyloid deposits are removed as compared to the subject without treatment of amyloid fibrils.

Claims 46-49 (canceled)

Claim 50 (currently amended): A method of removing amyloid deposits from a subject comprising administering to the subject amyloid fibrils comprising an immunoglobulin light chain polypeptide, heterologous to the amyloid fibrils in the subject, in an effective amount to generate an immune response, wherein the immune response promotes the removal of amyloid deposits from the subject.

Claim 51 (previously presented): A method of claim 50, wherein the subject is a mammal.

Claim 52 (previously presented): A method of claim 51, wherein the mammal is a human.

Claims 53-56 (canceled)

Claim 57 (previously presented): A method of claim 32, wherein the synthetic amyloid fibrils comprise recombinant protein or polypeptide.

Claim 58 (currently amended): A method of removing amyloid deposits from a subject comprising administering to the subject amyloid fibrils comprising a whole immunoglobulin light chain polypeptide, heterologous to the amyloid fibrils in the subject, in an effective amount to generate an immune response, wherein the immune response promotes the removal of amyloid deposits from the subject.

Claim 59 (currently amended): A pharmaceutical composition formulated for removing amyloid deposits from a subject comprising an effective amount of amyloid fibrils comprising an immunoglobulin light chain polypeptide or a whole light chain polypeptide, heterologous to the amyloid fibrils in the subject,.

Claim 60 (previously presented): A pharmaceutical composition of claim 59 comprising an immunoglobulin light chain polypeptide.

Claim 61 (previously presented): A pharmaceutical composition of claim 59 comprising a whole immunoglobulin light chain polypeptide.

Claim 62 (canceled)

Claim 63 (previously presented): A method of claim 32, wherein the synthetic amyloid fibrils comprise purified native protein or polypeptide.

Claim 64 (previously presented): A method of removing amyloid deposits from a subject comprising administering to the subject the composition of claim 59 in an effective amount to generate an immune response, wherein the immune response promotes the removal of amyloid deposits from the subject.

Claim 65 (previously presented): A pharmaceutical composition of claim 59, wherein the pharmaceutical composition further comprises a carrier.

Claim 66 (previously presented): A pharmaceutical composition of claim 59, wherein the phmarmaceutical composition further comprises an adjuvant.

Claim 67 (previously presented): A pharmaceutical composition of claim 66, wherein the adjuvant is selected from the group consisting of Freund's, BCG (bacilli Calmette-Guerin), Corynebacterium parvum, aluminum hydroxide (ALUM), lysolecithin, pluronic polyols, polyanions, and dinitrophenol.

Claim 68 (previously presented): A pharmaceutical composition of claim 67, wherein the adjuvant is selected from the group consisting of BCG, Corynebacterium parvum, and ALUM.

Claim 69 (new): The method of claim 1, wherein the immunoglobulin light chain polypeptide comprises the variable region.

Claim 70 (new): The method of claim 69, wherein the immunoglobulin light chain polypeptide comprises the κ or λ chain.